AKBA - Akebia Therapeutics, Inc.
IEX Last Trade
1.955
0.015 0.767%
Share volume: 67,767
Last Updated: Fri 27 Dec 2024 08:29:43 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.94
0.02
0.77%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2023-03-31 | 2022-12-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q1 2023 | Q4 2022 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-03 | 2023-05-08 | 2023-08-28 | 2023-08-28 | 2023-11-08 | 2024-03-14 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 521.804 M | 435.894 M | 276.858 M | 356.054 M | 253.712 M | 234.998 M | 241.703 M | 225.477 M | |
| Current Assets | 304.163 M | 237.512 M | 120.719 M | 185.182 M | 118.447 M | 109.602 M | 118.149 M | 112.944 M | |
| Inventories | 36.272 M | 40.039 M | 20.604 M | 21.568 M | 20.905 M | 18.442 M | 15.691 M | 25.532 M | |
| Other Current Assets | 42.129 M | 29.618 M | 25.381 M | 32.864 M | 24.398 M | 22.039 M | 20.243 M | 18.831 M | |
| Short Term Investments | 42.129 M | 29.618 M | 25.381 M | 32.864 M | 24.398 M | 22.039 M | 20.243 M | 18.831 M | |
| Total Receivables | 81.869 M | 23.094 M | 17.781 M | 40.284 M | 19.572 M | 22.592 M | 39.290 M | 26.620 M | |
| Current Cash | 143.893 M | 144.761 M | 56.953 M | 90.466 M | 53.572 M | 46.529 M | 42.925 M | 41.961 M | |
| Total Non-current Assets | 217.641 M | 198.382 M | 156.139 M | 170.872 M | 135.265 M | 125.396 M | 123.554 M | 112.533 M | |
| Property Plant Equipment | 6.035 M | 5.622 M | 4.816 M | 5.214 M | 4.419 M | 4.023 M | 3.629 M | 3.265 M | |
| Other Assets | 66.447 M | 56.612 M | 33.196 M | 34.530 M | 17.739 M | 17.276 M | 24.839 M | 23.192 M | |
| Intangible Assets | 90.106 M | 81.095 M | 63.074 M | 72.084 M | 54.063 M | 45.053 M | 36.042 M | 27.032 M | |
| Goodwill | 55.053 M | 55.053 M | 55.053 M | 59.044 M | 59.044 M | 59.044 M | 59.044 M | 59.044 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 521.804 M | 435.894 M | 276.858 M | 356.054 M | 253.712 M | 234.998 M | 241.703 M | 225.477 M | |
| Total liabilities | 459.504 M | 422.041 M | 291.210 M | 350.824 M | 280.519 M | 274.420 M | 272.287 M | 252.735 M | |
| Total current liabilities | 233.680 M | 187.965 M | 82.944 M | 129.536 M | 92.184 M | 79.702 M | 99.870 M | 66.487 M | |
| Accounts Payable | 24.944 M | 19.708 M | 12.577 M | 18.021 M | 11.776 M | 9.038 M | 14.635 M | 11.882 M | |
| Other liabilities | 194.091 M | 203.393 M | 154.552 M | 158.249 M | 157.609 M | 149.118 M | 146.287 M | 148.467 M | |
| Current long term debt | 98.158 M | 65.947 M | 24.000 M | 32.000 M | 24.000 M | 8.000 M | 17.500 M | 0.000 | |
| Long term debt | 31.733 M | 30.683 M | 53.714 M | 63.039 M | 30.726 M | 45.600 M | 26.130 M | 37.781 M | |
| Other liabilities | 194.091 M | 203.393 M | 154.552 M | 158.249 M | 157.609 M | 149.118 M | 146.287 M | 148.467 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 62.300 M | 13.853 M | -14.352 M | 5.230 M | -26.807 M | -39.422 M | -30.584 M | -27.258 M | |
| Common stock | 183.598 M | 183.882 M | 184.769 M | 184.051 M | 186.817 M | 188.306 M | 189.969 M | 204.955 M | |
| Retained earnings | -1.493 B | -1.545 B | -1.579 B | -1.557 B | -1.595 B | -1.610 B | -1.609 B | -1.627 B |